[go: up one dir, main page]

RU2012132705A - FABRIC STRUCTURES OBTAINED BY BIOENGINEERING, AND METHODS FOR PRODUCING AND USING THEM - Google Patents

FABRIC STRUCTURES OBTAINED BY BIOENGINEERING, AND METHODS FOR PRODUCING AND USING THEM Download PDF

Info

Publication number
RU2012132705A
RU2012132705A RU2012132705/10A RU2012132705A RU2012132705A RU 2012132705 A RU2012132705 A RU 2012132705A RU 2012132705/10 A RU2012132705/10 A RU 2012132705/10A RU 2012132705 A RU2012132705 A RU 2012132705A RU 2012132705 A RU2012132705 A RU 2012132705A
Authority
RU
Russia
Prior art keywords
bioengineered
stem cells
mesenchymal stem
construction according
bioengineering
Prior art date
Application number
RU2012132705/10A
Other languages
Russian (ru)
Other versions
RU2645473C2 (en
Inventor
Винсент РОНФАРД
Долорес БАКШ
Сяньянь ВАН
Мэттью Квин-мэн ВОН
Лан КАО
Парид САВА
Томас БОЛЛЕНБАХ
Есин ЕСИЛАЛАН
Original Assignee
Органодженезис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Органодженезис, Инк. filed Critical Органодженезис, Инк.
Publication of RU2012132705A publication Critical patent/RU2012132705A/en
Application granted granted Critical
Publication of RU2645473C2 publication Critical patent/RU2645473C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Биоинженерная конструкция, содержащая мезенхимальные стволовые клетки, выращенные в условиях для получения слоя внеклеточного матрикса, который синтезируется и собирается указанными мезенхимальными стволовыми клетками.2. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки получают из костного мозга, пуповины, плаценты, амниона, мышц, жировой ткани, кости, сухожилия или хряща.3. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки представляют собой пуповинные мезенхимальные стволовые клетки.4. Биоинженерная конструкция по п.3, отличающаяся тем, что указанные пуповинные мезенхимальные стволовые клетки выделены из пуповинной крови, субэндотелия пупочной вены или вартонова студня.5. Биоинженерная конструкция по п.3, отличающаяся тем, что указанные пуповинные мезенхимальные стволовые клетки представляют собой периваскулярные клетки пуповины человека (HUCPVC).6. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки представляют собой мезенхимальные стволовые клетки человека.7. Биоинженерная конструкция по любому из пп.1-6, отличающаяся тем, что указанные мезенхимальные стволовые клетки смешаны с фибробластами.8. Биоинженерная конструкция по п.7, отличающаяся тем, что указанные мезенхимальные стволовые клетки и фибробласты присутствуют по меньшей мере в двух отдельных слоях.9. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция имеет поры с диаметром в диапазоне от 10 мкм до 150 мкм, причем указанные поры могут иметь диаметр в диапазоне от 50 �1. A bioengineered construct containing mesenchymal stem cells grown under conditions to obtain an extracellular matrix layer that is synthesized and assembled by said mesenchymal stem cells. 2. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are obtained from bone marrow, umbilical cord, placenta, amnion, muscle, adipose tissue, bone, tendon or cartilage. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are umbilical mesenchymal stem cells. The bioengineered construction according to claim 3, characterized in that said umbilical cord mesenchymal stem cells are isolated from umbilical cord blood, umbilical vein subendothelium, or Wharton jelly. The bioengineered construction according to claim 3, characterized in that said umbilical mesenchymal stem cells are human perivascular umbilical cord cells (HUCPVC) .6. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are human mesenchymal stem cells. A bioengineered construct according to any one of claims 1 to 6, characterized in that said mesenchymal stem cells are mixed with fibroblasts. The bioengineered construction according to claim 7, characterized in that said mesenchymal stem cells and fibroblasts are present in at least two separate layers. The bioengineered structure according to claim 1, characterized in that said bioengineered structure has pores with a diameter in the range from 10 μm to 150 μm, and these pores can have a diameter in the range from 50

Claims (16)

1. Биоинженерная конструкция, содержащая мезенхимальные стволовые клетки, выращенные в условиях для получения слоя внеклеточного матрикса, который синтезируется и собирается указанными мезенхимальными стволовыми клетками.1. A bioengineered construct containing mesenchymal stem cells grown under conditions to obtain an extracellular matrix layer that is synthesized and assembled by said mesenchymal stem cells. 2. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки получают из костного мозга, пуповины, плаценты, амниона, мышц, жировой ткани, кости, сухожилия или хряща.2. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are obtained from bone marrow, umbilical cord, placenta, amnion, muscle, adipose tissue, bone, tendon or cartilage. 3. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки представляют собой пуповинные мезенхимальные стволовые клетки.3. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are umbilical mesenchymal stem cells. 4. Биоинженерная конструкция по п.3, отличающаяся тем, что указанные пуповинные мезенхимальные стволовые клетки выделены из пуповинной крови, субэндотелия пупочной вены или вартонова студня.4. The bioengineered construction according to claim 3, characterized in that said umbilical cord mesenchymal stem cells are isolated from umbilical cord blood, umbilical vein subendothelium, or Wharton jelly. 5. Биоинженерная конструкция по п.3, отличающаяся тем, что указанные пуповинные мезенхимальные стволовые клетки представляют собой периваскулярные клетки пуповины человека (HUCPVC).5. The bioengineered design according to claim 3, characterized in that said umbilical cord mesenchymal stem cells are perivascular human umbilical cord cells (HUCPVC). 6. Биоинженерная конструкция по п.1, отличающаяся тем, что указанные мезенхимальные стволовые клетки представляют собой мезенхимальные стволовые клетки человека.6. The bioengineered construction according to claim 1, characterized in that said mesenchymal stem cells are human mesenchymal stem cells. 7. Биоинженерная конструкция по любому из пп.1-6, отличающаяся тем, что указанные мезенхимальные стволовые клетки смешаны с фибробластами.7. Bioengineering design according to any one of claims 1 to 6, characterized in that said mesenchymal stem cells are mixed with fibroblasts. 8. Биоинженерная конструкция по п.7, отличающаяся тем, что указанные мезенхимальные стволовые клетки и фибробласты присутствуют по меньшей мере в двух отдельных слоях.8. The bioengineered construction according to claim 7, characterized in that said mesenchymal stem cells and fibroblasts are present in at least two separate layers. 9. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция имеет поры с диаметром в диапазоне от 10 мкм до 150 мкм, причем указанные поры могут иметь диаметр в диапазоне от 50 мкм до 100 мкм или от 80 мкм до 100 мкм.9. Bioengineering design according to claim 1, characterized in that said bioengineering design has pores with a diameter in the range from 10 μm to 150 μm, and these pores can have a diameter in the range from 50 μm to 100 μm or from 80 μm to 100 μm . 10. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция характеризуется средним Fmax, составляющим по меньшей мере 0,4 Н.10. Bioengineering design according to claim 1, characterized in that said bioengineering design is characterized by an average Fmax of at least 0.4 N. 11. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция имеет предел прочности на растяжение (UTS), равный по меньшей мере 0,4 МПа.11. Bioengineering design according to claim 1, characterized in that said bioengineering design has a tensile strength (UTS) of at least 0.4 MPa. 12. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция характеризуется по меньшей мере 0,4-кратным допуском упругой деформации относительно начальной длины.12. The bioengineered structure according to claim 1, characterized in that said bioengineered structure is characterized by at least 0.4-fold tolerance of elastic deformation relative to the initial length. 13. Биоинженерная конструкция по п.1, отличающаяся тем, что клетки указанной биоинженерной конструкции девитализированы.13. Bioengineering design according to claim 1, characterized in that the cells of the specified bioengineering design are devitalized. 14. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция дополнительно содержит одно или более из следующего: гиалуронан, КСФ-3, витронектин, гепарин, НМКА1, CXCL1, IL-6 (ИЛ-6), IL-8 (ИЛ-8), ФРЭС-А, ФРЭС-С, PDGF(ФРТ)-β, РЕСАМ1, CDH5, ANGPT1, ММР2, TIMP1 и TIMP3.14. The bioengineered construction according to claim 1, characterized in that said bioengineered construction further comprises one or more of the following: hyaluronan, KSF-3, vitronectin, heparin, HMCA1, CXCL1, IL-6 (IL-6), IL-8 (IL-8), FRES-A, FRES-S, PDGF (FRT) -β, RESAM1, CDH5, ANGPT1, MMP2, TIMP1 and TIMP3. 15. Биоинженерная конструкция по п.1, отличающаяся тем, что указанная биоинженерная конструкция дополнительно содержит противомикробный агент, фармацевтическое лекарственное средство, фактор роста, цитокин, пептид или белок.15. The bioengineered construct according to claim 1, characterized in that said bioengineered construct further comprises an antimicrobial agent, a pharmaceutical drug, growth factor, cytokine, peptide or protein. 16. Биоинженерная конструкция по п.1, отличающаяся тем, что площадь поверхности указанной биоинженерной конструкции сокращается по меньшей мере на 50% при высвобождении указанной биоинженерной конструкции из культурального субстрата. 16. The bioengineered structure according to claim 1, characterized in that the surface area of the specified bioengineered structure is reduced by at least 50% when the specified bioengineered structure is released from the culture substrate.
RU2012132705A 2010-01-14 2011-01-14 Tissue structures obtained by bioengineering, and methods for their production and application RU2645473C2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29507310P 2010-01-14 2010-01-14
US61/295,073 2010-01-14
US33793810P 2010-02-12 2010-02-12
US61/337,938 2010-02-12
US34772510P 2010-05-24 2010-05-24
US61/347,725 2010-05-24
PCT/US2011/021362 WO2011088365A1 (en) 2010-01-14 2011-01-14 Bioengineered tissue constructs and methods for producing and using thereof

Publications (2)

Publication Number Publication Date
RU2012132705A true RU2012132705A (en) 2014-02-20
RU2645473C2 RU2645473C2 (en) 2018-02-21

Family

ID=43881131

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012132705A RU2645473C2 (en) 2010-01-14 2011-01-14 Tissue structures obtained by bioengineering, and methods for their production and application

Country Status (12)

Country Link
US (1) US20110293667A1 (en)
EP (1) EP2524034A1 (en)
JP (3) JP2013517292A (en)
CN (2) CN107802890A (en)
AU (1) AU2011205674A1 (en)
BR (1) BR112012017463A2 (en)
CA (1) CA2787050A1 (en)
IL (1) IL220903A0 (en)
MX (1) MX354068B (en)
RU (1) RU2645473C2 (en)
SG (1) SG182508A1 (en)
WO (1) WO2011088365A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986377B2 (en) 2009-07-21 2015-03-24 Lifecell Corporation Graft materials for surgical breast procedures
US20120143228A1 (en) 2010-08-30 2012-06-07 Agency For Science Technology And Research Adhesive structure with stiff protrusions on adhesive surface
US9492952B2 (en) 2010-08-30 2016-11-15 Endo-Surgery, Inc. Super-hydrophilic structures
EP2714111B1 (en) * 2011-05-31 2021-03-17 LifeCell Corporation Adipose tissue matrices
EP2753247A4 (en) * 2011-09-06 2015-07-08 Stem Cell Surgical Llc SURGICAL SUTURES AND METHODS OF MAKING AND USING SUTURES
JP6159729B2 (en) 2011-11-08 2017-07-05 オークソセル ラボラトリーズ， インコーポレイテッド System and method for treating cells
WO2013102085A1 (en) * 2011-12-29 2013-07-04 Ethicon, Inc. Adhesive structure with tissue piercing protrusions on its surface
WO2013106556A2 (en) 2012-01-13 2013-07-18 Lifecell Corporation Breast prostheses, methods of manufacturing breast prostheses, and methods of treatment using breast prostheses
CN102599991A (en) * 2012-03-20 2012-07-25 中山大学中山眼科中心 Application of beautifying cornea lens
US8969648B2 (en) 2012-04-06 2015-03-03 Ethicon, Inc. Blood clotting substrate and medical device
US8926881B2 (en) 2012-04-06 2015-01-06 DePuy Synthes Products, LLC Super-hydrophobic hierarchical structures, method of forming them and medical devices incorporating them
ES2647979T3 (en) * 2012-06-21 2017-12-27 Lifecell Corporation Implantable prosthesis that has acellular tissue fixations
US9533072B2 (en) * 2012-10-08 2017-01-03 Cormatrix Cardiovascular, Inc. Reinforced vascular prostheses
ES2764146T3 (en) * 2013-02-08 2020-06-02 Acell Inc Methods for making bioactive gels from extracellular matrix material
MX366410B (en) 2013-02-12 2019-07-08 Replicel Life Sciences Inc Compositions and methods for treating and repairing tendons.
EP2956184B9 (en) * 2013-02-14 2018-04-25 Council of Scientific and Industrial Research Silk based porous scaffold and a process for the preparation thereof
CA2919374C (en) 2013-07-30 2019-12-03 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US20160184364A1 (en) * 2013-08-14 2016-06-30 Stempeutics Research Pvt. Ltd. Management of osteoarthritis using pooled allogeneic mesenchymal stem cells
JP6145511B2 (en) * 2013-09-25 2017-06-14 富士フイルム株式会社 Biocompatible polymer porous body production method, biocompatible polymer porous body, biocompatible polymer block, and cell structure
US10959839B2 (en) * 2013-10-08 2021-03-30 Edwards Lifesciences Corporation Method for directing cellular migration patterns on a biological tissue
GB201317889D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product and use
CL2013003066A1 (en) * 2013-10-22 2014-07-25 Univ Chile Composition for treatment of wounds because it comprises support matrix and stem cells mesenchymics of wharton jelly; method for treating wounds comprising applying said composition
RU2559921C2 (en) * 2013-11-01 2015-08-20 Игорь Иванович Агапов Method of restoring small intestine integrity
CN104726398A (en) * 2013-12-20 2015-06-24 江阴司特易生物技术有限公司 Preparation method of immobilized all-anthropogenic ECM coating matrix
TW201538730A (en) 2014-02-12 2015-10-16 Replicel Life Sciences Inc Compositions and methods for treating bone, joints and cartilage
EP3142586B1 (en) * 2014-05-14 2020-09-30 President and Fellows of Harvard College Catheter device for transmitting and reflecting light
USD748462S1 (en) 2014-08-11 2016-02-02 Auxocell Laboratories, Inc. Centrifuge clip
US9993748B2 (en) 2014-08-11 2018-06-12 Auxocell Laboratories, Inc. Centrifuge clip and method
WO2016143746A1 (en) * 2015-03-12 2016-09-15 一般財団法人化学及血清療法研究所 Anti-adhesion material and artificial biological membrane each comprising decellularized tissue
CN104800891B (en) * 2015-05-20 2017-03-29 苏州大学附属第一医院 A kind of extracellular matrix biomaterial for strengthening In vitro culture mesenchymal stem cell biological anti-oxidation function, preparation method and applications
CN105769381B (en) * 2015-05-26 2018-04-17 南通大学 A kind of biological sticking patch for tissue damage reparation
CN104958319A (en) * 2015-06-01 2015-10-07 成都清科生物科技有限公司 Mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and preparing method for preparation
WO2017003877A1 (en) * 2015-06-30 2017-01-05 Lattice Biologics Inc. Modified extracellular matrix for enhanced stem cell homing and engraftment
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US10842612B2 (en) 2015-08-21 2020-11-24 Lifecell Corporation Breast treatment device
WO2017059089A1 (en) * 2015-09-29 2017-04-06 Anicell Biotech, Llc Methods and articles of manufacture for the treatment of animals
CN105535946A (en) * 2015-12-14 2016-05-04 北京大学第一医院 Application of transglutaminase in strengthening corneal mechanical properties and biological preparation
WO2017172638A1 (en) * 2016-03-29 2017-10-05 Smsbiotech, Inc. Compositions and methods for using small mobile stem cells
CA3019446A1 (en) * 2016-03-30 2017-10-05 Stembiosys, Inc. Bone marrow stromal cell derived extracellular matrix protein extract and uses thereof
CA3035256A1 (en) 2016-08-31 2018-03-08 Lifecell Corporation Breast treatment device
US11730696B2 (en) * 2016-10-20 2023-08-22 Australian Foundation for Diabetes Research Cell associated scaffolds for delivery of agents
CN106581760A (en) * 2016-11-08 2017-04-26 华南生物医药研究院 Special treatment method for enhancing cell activity
CN106619721A (en) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 Novel method for enhancing cell viability
CN106563161A (en) * 2016-11-08 2017-04-19 华南生物医药研究院 Novel drug combination for cosmetic purposes
WO2018123814A1 (en) 2016-12-28 2018-07-05 株式会社高研 High-strength collagen sponge
US10368991B2 (en) * 2017-02-06 2019-08-06 C. R. Bard, Inc. Device and associated percutaneous minimally invasive method for creating a venous valve
KR20180099482A (en) * 2017-02-27 2018-09-05 고려대학교 산학협력단 Method for preparing decellularized tissue using hydrogel polymer and decellularized tissue prepared therefrom
WO2018231726A1 (en) * 2017-06-12 2018-12-20 The University Of North Carolina At Chapel Hill Patch graft compositions for cell engraftment
CN107550935A (en) * 2017-09-11 2018-01-09 上海亚睿生物科技有限公司 A kind of biological gel for treating joint disease and its application
CL2017002357A1 (en) * 2017-09-16 2018-04-20 Cells For Cells S A Method of obtaining a composition that contains a specific population of umbilical cord mesenchymal cells and their uses
CN112980782A (en) 2017-10-25 2021-06-18 雪拉托兹治疗株式会社 Novel musculoskeletal system stem cells
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
CN108144128B (en) * 2018-02-07 2021-11-05 陕西佰傲再生医学有限公司 Multi-time cross-linking breast patch and preparation method thereof
CN108543116B (en) * 2018-05-02 2021-04-27 深圳市华异生物科技有限责任公司 Sodium alginate and gelatin composite hydrogel 3D islet scaffold and preparation method thereof
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
EP3861103A1 (en) 2018-10-03 2021-08-11 Stembiosys, Inc. Amniotic fluid cell-derived extracellular matrix and uses thereof
CN109793927A (en) * 2019-01-24 2019-05-24 中国人民解放军军事科学院军事医学研究院 Preparation method of silk fibroin porous scaffold based on extracellular derived matrix modification
KR102639023B1 (en) 2019-02-21 2024-02-20 스템바이오시스, 인크. Methods for cardiomyocyte maturation on amniotic fluid cell-derived ECM, cellular structure, and use for cardiotoxicity and proarrhythmia screening of drug compounds
CN110075357A (en) * 2019-04-02 2019-08-02 浙江大学 A kind of preparation method of fat stem cell and the compound bone renovating material of nanometer fibroin
WO2020207426A1 (en) * 2019-04-10 2020-10-15 上海交通大学医学院附属上海儿童医学中心 In vivo implantable micropore pocket, use method therefor and application thereof
US11298220B2 (en) 2019-05-03 2022-04-12 Lifecell Corporation Breast treatment device
CN110106148B (en) * 2019-05-16 2020-10-13 中国人民解放军军事科学院军事医学研究院 Tissue engineering nerve tissue and construction method thereof
CN110409059A (en) * 2019-07-30 2019-11-05 北京化工大学常州先进材料研究院 Preparation method of acrylylated PGS nanofiber membrane reinforced by dimethylaminoethyl methacrylate
CN112342187A (en) * 2019-08-06 2021-02-09 中晶生物技术股份有限公司 Chondrocyte culture medium and preparation method thereof
CN110904044B (en) * 2019-12-17 2022-07-19 陕西师范大学 Three-dimensional culture method of tumor stem cells
CN111407353A (en) * 2020-02-26 2020-07-14 邹洪 Novel ligature nail clamp made of fibroin material
US11725112B2 (en) * 2020-02-28 2023-08-15 Lawrence Livermore National Security, Llc Three-dimensional printed porous silicone matrix using leachable porogen
RU2749801C1 (en) * 2020-03-06 2021-06-17 Галина Мироновна Могильная Method for recovery of lost volume of derma experiment in rats
US20210393852A1 (en) * 2020-06-19 2021-12-23 Mimedx Group, Inc. Meshed umbilical cord tissue grafts
CN111690604A (en) * 2020-06-24 2020-09-22 杭州原生生物科技有限公司 MSC in-vitro amplification method
KR102527152B1 (en) * 2021-02-15 2023-04-28 울산과학기술원 Artificial electronic skin comprising ferroelectric biodegradable polymer layer
CN113456893B (en) * 2021-07-26 2022-04-26 温州医科大学附属眼视光医院 A kind of preparation method of blue-stained amniotic basement membrane coated with fibrinogen
EP4460342A4 (en) * 2022-01-04 2025-11-19 Ronawk Inc Acellular substrates and methods for their production
CN115105637B (en) * 2022-07-28 2023-11-10 上海交通大学医学院附属第九人民医院 Application of subconjunctival fibroblast acellular matrix in conjunctival reconstruction
WO2024092220A2 (en) * 2022-10-28 2024-05-02 University Of Connecticut Prosthetic device for tissue regeneration
CN117582557B (en) * 2024-01-19 2024-03-19 四川恒普科技有限公司 Demineralized bone fiber and preparation method thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Cell culture medium containing insulin or an insulin-like growth factor, transferrin or ferrous ion and triiodothyronine or thyroxin and a method for its use
US5460962A (en) 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
CA2189421A1 (en) 1994-05-11 1995-11-23 Peter K. Mays Collagen from cell cultures
AU4330597A (en) * 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US5993844A (en) * 1997-05-08 1999-11-30 Organogenesis, Inc. Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix
US6291240B1 (en) * 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
BR9915476A (en) 1998-11-19 2002-01-02 Organogenesis Inc Fabric constructs made by bioengineering and methods for their production and use
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
JP5398941B2 (en) * 1999-08-05 2014-01-29 エイビーティー ホールディング カンパニー Pluripotent adult stem cell and method for isolating the same
AU2002354915B8 (en) * 2001-07-16 2008-04-17 Depuy Products, Inc. Porous extracellular matrix scaffold and method
EP1452586B1 (en) * 2001-10-30 2012-05-30 Nc Medical Research Inc. Method of inducing differentiation of mesodermal stem cells into nervous system cells
EP1451299A4 (en) * 2001-12-11 2008-03-05 Cytograft Tissue Engineering I Tissue engineered cellular sheets, methods of making and use thereof
DE602004028803D1 (en) * 2003-02-11 2010-10-07 John E Davies PRECURSOR CELLS FROM THE WHARTON SULCE OF HUMAN NECK LOCKS
DE602004030254D1 (en) * 2003-08-01 2011-01-05 Two Cells Co Ltd SCAFFOLD FREE, SELF ORGANIZED, 3 DIMENSIONAL, SYNTHETIC TISSUE
US20050288796A1 (en) * 2004-06-23 2005-12-29 Hani Awad Native soft tissue matrix for therapeutic applications
US7598083B2 (en) * 2004-10-29 2009-10-06 Centocor, Inc. Chemically defined media compositions
US8728463B2 (en) * 2005-03-11 2014-05-20 Wake Forest University Health Science Production of tissue engineered digits and limbs
WO2006102063A2 (en) * 2005-03-19 2006-09-28 Cook Biotech Incorporated Prosthetic implants including ecm composite material
JP4745750B2 (en) * 2005-08-01 2011-08-10 株式会社ツーセル Serum-free medium for animal stem cell culture
ATE449165T1 (en) * 2005-08-26 2009-12-15 Seoul Nat Univ Ind Foundation MULTIPOTENT BLOOD STEM CELLS FROM THE UMBILE CORD AND CELL TREATMENT AGENTS THEREFOR FOR THE TREATMENT OF ISCHEMIC DISEASE
EP2431063B1 (en) * 2005-08-26 2015-06-17 Regents of the University of Minnesota Decellularization and recellularization of organs and tissues
JP2009528856A (en) * 2006-03-03 2009-08-13 オルガノジェネシス インク． Oral tissue regeneration and repair
CN101412985B (en) * 2007-10-15 2012-06-13 华东理工大学 Serum-free medium for in vitro cultivation and amplification of mesenchymal stem cells
CN100563728C (en) * 2007-10-19 2009-12-02 中国人民解放军第四军医大学 Contain organization engineering skin of peripheral hematopoietic stem cells and preparation method thereof
US20110293666A1 (en) * 2007-11-28 2011-12-01 Xianyan Wang Bioengineered Tissue Constructs and Methods for Production and Use
CA2706855A1 (en) * 2007-11-28 2009-06-04 Organogenesis, Inc. Bioengineered tissue constructs and methods for production and use
RU86455U1 (en) * 2008-04-22 2009-09-10 ФГУ "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" РФ BIO ENGINEERING DESIGN
US9023644B2 (en) * 2011-12-16 2015-05-05 Wisconsin Alumni Research Foundation FGF having enhanced stability

Also Published As

Publication number Publication date
JP2016182126A (en) 2016-10-20
JP2013517292A (en) 2013-05-16
MX354068B (en) 2018-02-09
SG182508A1 (en) 2012-08-30
AU2011205674A1 (en) 2012-08-09
JP2018117643A (en) 2018-08-02
BR112012017463A2 (en) 2015-09-15
EP2524034A1 (en) 2012-11-21
CN107802890A (en) 2018-03-16
RU2645473C2 (en) 2018-02-21
WO2011088365A1 (en) 2011-07-21
MX2012008215A (en) 2012-10-15
CA2787050A1 (en) 2011-07-21
CN102892880A (en) 2013-01-23
US20110293667A1 (en) 2011-12-01
IL220903A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
RU2012132705A (en) FABRIC STRUCTURES OBTAINED BY BIOENGINEERING, AND METHODS FOR PRODUCING AND USING THEM
Oualla-Bachiri et al. From grafts to human bioengineered vascularized skin substitutes
Guo et al. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases
Hosseini et al. Regenerative medicine applications of mesenchymal stem cells
Xu et al. Circulating mesenchymal stem cells and their clinical implications
Takahashi Role of the SDF-1/CXCR4 system in myocardial infarction
Piccoli et al. Improvement of diaphragmatic performance through orthotopic application of decellularized extracellular matrix patch
Godwin et al. Extracellular matrix considerations for scar-free repair and regeneration: insights from regenerative diversity among vertebrates
Spiller et al. Macrophages modulate engineered human tissues for enhanced vascularization and healing
Singh Mohal et al. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications
Haque et al. Role of the CXCR4-SDF1-HMGB1 pathway in the directional migration of cells and regeneration of affected organs
Li et al. Porous fish collagen for cartilage tissue engineering
Li et al. Mesenchymal stem cell–based therapy for nonhealing wounds: today and tomorrow
Gugatschka et al. Regenerative medicine of the larynx. Where are we today? A review
JP2016515533A5 (en)
Wobma et al. Paracrine effects of mesenchymal stromal cells cultured in three-dimensional settings on tissue repair
JP2010529987A (en) Treatment of diseases and disorders using self-replicating colony-forming cells cultured and grown in vitro
JP2010529987A5 (en)
RU2014136711A (en) STROMAL STEM CELLS
Knecht et al. Mechanobiological principles influence the immune response in regeneration: implications for bone healing
Thurairajah et al. Trauma and stem cells: biology and potential therapeutic implications
Hassanshahi et al. Critical limb ischemia: Current and novel therapeutic strategies
Athanassopoulos et al. Microvessel networks in pre-formed in artificial clinical grade dermal substitutes in vitro using cells from haematopoietic tissues
Du et al. A fibrous hybrid patch couples cell-derived matrix and poly (l-lactide-co-caprolactone) for endothelial cells delivery and skin wound repair
WO2022004816A1 (en) Cranial nerve disorder therapeutic agent including culture supernatant of tissue cells derived from fetal appendage

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190115